Welcome to our dedicated page for PIII.W news (Ticker: PIII.W), a resource for investors and traders seeking the latest updates and insights on PIII.W stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PIII.W's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PIII.W's position in the market.
P3 Health Partners reported a strong revenue growth of 46% for Q4 2021 and 32% for the full year, projecting 2022 revenue up to $1 billion (a 56% increase). The company aims for 95,000 at-risk Medicare Advantage members by year-end, a 42% rise. Adjusted EBITDA is expected to improve significantly, with profitability anticipated by 2024. Despite a net loss of up to $95 million for Q4, a robust cash position of $140 million at year-end supports operations. P3 will file for a late 10-K extension, expecting to release detailed results by April 15, 2022.
P3 Health Partners, Inc. (NASDAQ: PIII), a physician-led population health management company, announced its participation in three investor conferences in March 2022. The company will present at the Cowen 42nd Annual Healthcare Conference on March 9, attend the 34th Annual ROTH Conference on March 14 in Dana Point, CA, and participate in the Barclays Global Healthcare Conference on March 16 in Miami, FL. Live webcasts will be available on P3’s investor relations website, providing access to presentations and replays.
P3 Health Partners has successfully acquired Medcore HP and Omni IPA Medical Group, adding over 10,500 Medicare Advantage members in California. This acquisition marks P3's entry into its fifth state, enhancing its national expansion strategy.
Medcore HP is licensed under California's Knox-Keene Act, allowing it to manage global risk for its members, while Omni IPA comprises over 400 healthcare providers. CEO Sherif Abdou emphasized that this move aligns with P3's mission to improve healthcare outcomes through value-based care.
P3 Health Partners (NASDAQ: PIII) has announced its participation in the 40th Annual J.P. Morgan Healthcare Conference, scheduled for January 12, 2022. CEO Dr. Sherif Abdou and the management team will present virtually at 5:15 p.m. ET. Interested parties can access the live webcast on P3's investor website, with a replay available afterwards. P3 focuses on patient-centered, physician-led population health management, aiming to enhance patient outcomes while reducing care costs through integrated care models and technology.
P3 Health Partners has completed its business combination with Foresight Acquisition Corp., with trading commencing on December 6, 2021, under the ticker symbols PIII and PIIIW on Nasdaq. The merger positions P3 as a public company aiming to improve population health management through its value-based care model, which focuses on empowering patients and providers. P3's management team, led by physician-experts, is committed to expanding operations and addressing significant healthcare challenges, including rising costs and access issues.
